News | July 30, 2009

New Data on Contrast Media, Kidney Damage May Impact Guidelines

July 30, 2009 - The iso-omolar contrast medium iodixanol does not yield lower rates of contrast-induced acute kidney injury (CI-AKI) than low-osmolar contrast media (LOCM), according to a meta-analysis published in the July 2009 issue of JACC: Cardiovascular Interventions.

Could these findings change current ACC/AHA guidelines, which give a class IA recommendation for iso-osmolar contrast media in patients with chronic kidney disease undergoing coronary angiography?

In the study, a team of researchers at the University of Michigan Medical School led by Hitinder Gurm, M.D., analyzed pooled data from 16 trials conducted between 1980 and 2008 that included 2,763 subjects. The studies consistently ascertained renal function data from patients randomized to either LOCM or iodixanol. The primary endpoint for the meta-analysis was the incidence of CI-AKI as defined by each individual study protocol.

Kidney injury occurred in 128 of 1,379 (9.3%) patients who received iodixanol vs. 158 of 1,375 (11.5%) patients who received LOCM. There was a trend toward a reduced relative risk of CI-AKI with iodixanol compared to LOCM as a whole, although the difference was not significant. After looking at individual types of contrast media, iodixanol did offer a significant advantage in some cases (table 1). Because only 1 study used iomeprol, an analysis was not conducted for this agent. Further, the risk of mortality and need for hemodialysis were similar between the iodixanol and LOCM groups.

This is contrary to earlier research suggesting iodixanol caused less kidney damage than LOCM. This conclusion led to the current ACC/AHA guidelines recommending iso-osmolar contrast media in NSTE ACS patients with chronic kidney disease undergoing angiography.

In light of the new data, the ACC/AHA guidelines may change, and subsequently drive the adoption of less expensive imaging alternatives that are just as effective as the more costly iodixanol, such as Bracco’s iopamidol or Isovue.

For more information: www.bracco.com

Related Content

Voyageur Minerals to Begin Manufacturing Barium Contrast Products With Chief Medical Supply
News | Contrast Media | November 14, 2018
Voyageur Minerals Ltd. signed a joint venture agreement with Chief Medical Supply Ltd (CM) of Calgary, Alberta to...
Osprey Medical and GE Healthcare Launch Acute Kidney Injury Educational Program
News | Angiography | September 25, 2018
September 21, 2018 — Osprey Medical announced a collaboration with GE Healthcare on Osprey’s Be Kind to Kidneys campa
Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore co
Scientists Develop New MRI Tool for Cancer Diagnosis and Therapy

Researchers in the laboratory ‘Biomedical Nanomaterials’ of NUST MISIS. Image courtesy of PR Newsfoto/NUST MISIS.

News | Oncology Diagnostics | August 24, 2018
A European research group has developed a system that allows doctors to both improve the accuracy of diagnosing...
Iron Outperforms Gadolinium as MRI Contrast Agent

Scientists at Rice's Laboratory for Nanophotonics added iron chelates (blue) and fluorescent dye (red) to multi-layered gold nanomatryoshkas to create particles that can be used for disease therapy and diagnostics. The "theranostic" nanoparticles have a core of gold (left) that is covered by silica containing the diagnostic iron and dye, which is covered by an outer shell of gold. The particles are about 20 times smaller than a red blood cell, and by varying the thickness of the layers, LANP scientists can tune the nanomatryoshkas to convert light into cancer-killing heat. (Image courtesy of Luke Henderson/Rice University)

News | Contrast Media | August 22, 2018
Rice University nanoscientists have demonstrated a method for loading iron inside nanoparticles to create magnetic...
Guerbet Partners With Imalogix on Dose Optimization With Artificial Intelligence
News | Radiation Dose Management | August 14, 2018
August 14, 2018 — Guerbet LLC USA announced a commercial partnership with Imalogix, a provider of...
Videos | Contrast Media | August 03, 2018
Lawrence Tanenbaum, M.D., FACR, vice president and director of advanced imaging at RadNet, discusses the latest resea
Guerbet, IBM Watson Health Partner on Artificial Intelligence for Liver Imaging
News | Clinical Decision Support | July 10, 2018
Guerbet announced it has signed an exclusive joint development agreement with IBM Watson Health to develop an...
Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
OptiStar Elite injector
Feature | Contrast Media Injectors | March 07, 2018 | Grand View Research Inc.
The global contrast media injectors market is expected to reach $1.4 billion by 2025, growing at a compound annual...